# ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

> **NCT00959959** · PHASE1 · COMPLETED · sponsor: **LTN PHARMACEUTICALS, INC.** · enrollment: 49 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** TOK-001
- **DRUG:** TOK-001
- **DRUG:** TOK-001
- **DRUG:** TOK-001
- **DRUG:** TOK-001
- **DRUG:** TOK-001
- **DRUG:** TOK-001
- **DRUG:** TOK-001

## Key facts

- **NCT ID:** NCT00959959
- **Lead sponsor:** LTN PHARMACEUTICALS, INC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-08
- **Final completion:** 2012-08
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959959, "ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00959959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*